Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder
Status:
Completed
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into
our program of outpatient detoxification and naltrexone induction followed by a
relapse-prevention treatment with Extended release-naltrexone (XR-NTX) . Eligible
participants will be randomly assigned to adjunctive treatment with lorcaserin (N = 40), or
placebo (N = 20) with weekly therapy.